Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AQP1 | P29972 | 3/20 | 0.52 |
| ▸ | PRKAB2 | O43741 | 2/20 | 0.37 |
| ▸ | PRKAG1 | P54619 | 2/20 | 0.37 |
| ▸ | PRKAA2 | P54646 | 2/20 | 0.37 |
| ▸ | PRKAA1 | Q13131 | 2/20 | 0.37 |
| ▸ | PRKAG3 | Q9UGI9 | 2/20 | 0.37 |
| ▸ | PRKAG2 | Q9UGJ0 | 2/20 | 0.37 |
| ▸ | PRKAB1 | Q9Y478 | 2/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | RPS6KA2 | Q15349 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4232160 | 0.91 | AQP1 (0.51) | AQP1PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL4226451 | 0.87 | PRKAB2 (0.50) | AQP1PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL4226803 | 0.86 | PRKAB2 (0.42) | AQP1PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL4230313 | 0.84 | AQP1 (0.48) | AQP1PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL4221735 | 0.84 | AQP1 (0.62) | AQP1PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL4223573 | 0.84 | AQP1 (0.47) | AQP1PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL4595447 | 0.84 | AQP1 (0.54) | AQP1PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL4235396 | 0.83 | AQP1 (0.54) | AQP1HTR2ADPP4 | |
| SCHEMBL4223606 | 0.83 | AQP1 (0.57) | AQP1HTR2ADPP4SLC6A2SLC6A4 | |
| SCHEMBL4234532 | 0.83 | AQP1 (0.57) | AQP1PRKAB2PRKAG1PRKAA2PRKAA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7435837-B2 | Dihydrobenzofuranyl alkanamine derivatives and methods for using same | WYETH (US) | 2008-10-14 | — | — | US | claimed |
| US-20080193732-A1 | LUMINESCENT FIBER AND MATERIAL THEREOF | TAIWAN TEXTILE RESEARCH INSTITUTE (TW) | 2008-08-14 | — | — | US | claimed |
| US-7396857-B2 | Therapeutic combinations for the treatment or prevention of depression | WYETH (US) | 2008-07-08 | — | — | US | claimed |
| EP-1898895-A2 | TREATMENT OF DRUG ABUSE | Wyeth (US) | 2008-03-19 | — | — | EP | claimed |
| EP-1879569-A2 | THERAPEUTIC COMBINATIONS FOR THE TREATMENT OR PREVENTION OF PSYCHOTIC DISORDERS | Wyeth (US) | 2008-01-23 | — | — | EP | claimed |
| EP-1874292-A2 | METHODS FOR MODULATING BLADDER FUNCTION | Wyeth (US) | 2008-01-09 | — | — | EP | claimed |
| EP-1871355-A1 | NEW THERAPEUTIC COMBIANATIONS FOR THE TREATMENT OR PREVENTION OF DEPRESSION | Wyeth (US) | 2008-01-02 | — | — | EP | claimed |
| EP-1871354-A1 | TREATMENT OF PAIN | Wyeth (US) | 2008-01-02 | — | — | EP | claimed |
| US-20070225334-A1 | Methods for treating cognitive and other disorders | WYETH (US) | 2007-09-27 | — | — | US | claimed |
| JP-2007509174-A | — | — | 2007-04-12 | — | — | JP | claimed |
| US-20060258712-A1 | Methods for modulating bladder function | WYETH (US) | 2006-11-16 | — | — | US | claimed |
| US-20060258739-A1 | Dihydrobenzofuran derivatives and uses therof | WYETH (US) | 2006-11-16 | — | — | US | claimed |
| WO-2006116221-A2 | THERAPEUTIC COMBINATIONS FOR THE TREATMENT OR PREVENTION OF PSYCHOTIC DISORDERS | WYETH (US) | 2006-11-02 | — | — | WO | claimed |
| WO-2006116148-A2 | (7-ARLYSUBSTITUTED 2, 3-DIHYDR0-1-BENZ0FURAN-2-YL) ALKYLAMINES IN THE TREATMENT' OF SUBSTANCE ABUSE | WYETH (US) | 2006-11-02 | — | — | WO | claimed |
| WO-2006116149-A1 | NEW THERAPEUTIC COMBIANATIONS FOR THE TREATMENT OR PREVENTION OF DEPRESSION | WYETH (US) | 2006-11-02 | — | — | WO | claimed |
| WO-2006116169-A2 | METHODS FOR MODULATING BLADDER FUNCTION | WYETH (US) | 2006-11-02 | — | — | WO | claimed |
| WO-2006116171-A1 | TREATMENT OF PAIN | WYETH (US) | 2006-11-02 | — | — | WO | claimed |
| EP-1675840-A1 | DIHYDROBENZOFURANYL ALKANAMINE DERIVATIVES AS 5HT2C AGONISTS | Wyeth a Corporation of the State of Delaware (US) | 2006-07-05 | — | — | EP | claimed |
| US-20050143452-A1 | Dihydrobenzofuranyl alkanamine derivatives and methods for using same | WYETH (US) | 2005-06-30 | — | — | US | claimed |
| WO-2005044812-A1 | DIHYDROBENZOFURANYL ALKANAMINE DERIVATIVES AS 5HT2C AGONISTS | WYETH A CORPORATION OF THE STATE OF DELAWARE (US) | 2005-05-19 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225334-A1 | Methods for treating cognitive and other disorders | CHAT, COMT, ACHE | AQP1 1312/4885PRKAB2 2928/4885PRKAG1 3153/4885 |
| US-20060258739-A1 | Dihydrobenzofuran derivatives and uses therof | HTR1F, HTR2C, HTR3D | AQP1 3184/4885PRKAB2 4363/4885PRKAG1 4343/4885 |
| US-20060258712-A1 | Methods for modulating bladder function | PDE3A, PDE3B, PDE2A | AQP1 137/4885PRKAB2 1021/4885PRKAG1 1420/4885 |
| US-20050143452-A1 | Dihydrobenzofuranyl alkanamine derivatives and methods for using same | HTR2C, HTR1A, HTR3A | AQP1 1105/4885PRKAB2 2598/4885PRKAG1 2441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.